Lv2
198 积分 2025-03-05 加入
Clinicopathologic characteristics of prefibrotic-early primary myelofibrosis in Chinese patients
4小时前
已完结
Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms
4天前
已完结
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
7天前
已完结
Fibroblast and myofibroblast activation in normal tissue repair and fibrosis
7天前
已完结
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
11天前
已完结
Combination treatments for myelofibrosis in JAK inhibitor-naive patients: evidence, rationale, and clinical direction
13天前
已完结
Navigating diagnostic shifts: A comparative review of the WHO 5th edition and ICC 2022 classifications of myeloid neoplasms
13天前
已完结
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis
13天前
已完结
How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes
18天前
已完结
Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms
19天前
已完结
皖公网安备34019202002308
